George Dawson (@dawso007), MD, addiction and neuropsychiatrist in Minnesota, joins Chadi to discuss mental illness and COVID – of having the virus itself, as well as the result of isolation and lack of social interaction. Dr. Dawson shares how individuals with drug or alcohol addictions have struggled to stay sober while being stuck at home without in-person meetings and human interaction, whether there is reason to believe the COVID lockdowns and social restrictions have worse health ramificati...
Apr 13, 2021•46 min
Krishna Komanduri (@drkomanduri), MD, chief of the division of transplantation and cellular therapy, University of Miami Sylvester Comprehensive Cancer Center, joins the show to provide a fascinating account of the history of allogeneic and autologous transplantation, the discovery of the difference between B cells and T cell, and up through modern cellular therapy with a forecast for the future decades. This is a crash course in cellular and CAR-T therapy that you won’t want to miss.
Apr 06, 2021•1 hr 3 min
Chadi invites Amy Barhorst (@amybarnhorst), MD, and Rocco Pallin, colleagues at UC Davis Health, to tackle the stigma and underdiagnosing of mental health in America and how mental illness intersects with gun violence in this country. The experts delve into whether community and person-to-person violence should be largely attributed to mental illness as well as why policy changes are the clearest way to eliminate mass shootings. Then, the conversation pivots to a true story of how their Review a...
Mar 30, 2021•1 hr 2 min
Aziz Nazha (@AzizNazhaMD), MD, former hem/onc at Cleveland Clinic, self-taught computer science expert, and now practice manager in the Data and Machine Learning Team at Amazon Web Services, joins the show to discuss artificial intelligence (AI) and machine learning from an entirely unique perspective. He details the pitfalls of unstructured healthcare data, privacy and ownership issues related to healthcare data and whether hospitals should be allowed to sell their patient data, why AI lagged i...
Mar 23, 2021•49 min
Chadi is joined by Priya Sampathkumar (@PSampathkumarMD), MD, infectious disease specialist and hospital epidemiologist, Mayo Clinic, to detail the COVID vaccine effort over the past 12 months and how the currently approved ones came to be safe and effective in such a short period of time. She then compares each vaccine in relation to their clinical trials and study populations, side effects (including some rare ones), and efficacy. Chadi and Dr. Sampathkumar converse on what it will take for he...
Mar 16, 2021•52 min
Andrew Foy (@AndrewFoy82), MD, cardiologist at Penn State University, joins the show to discuss publishing bias for medical research along with the psychological dilemma as a result of the pandemic of sacrificing personal liberties for the safety of others. The conversation pivots to Dr. Foy’s experience with boxing at a young age and how he eventually channeled that love into promoting the sport. How can promoting a boxing match be similar to planning a wedding? How can a full-time cardiologist...
Mar 09, 2021•59 min
Toni Choueiri (@DrChoueiri), MD, Dana-Farber Cancer Institute, joins the show to guest host a discussion with Rana McKay (@DrRanaMcKay), MD, UC San Diego, and Alicia Morgans (@CaPsurvivorship), MD, MPH, Northwestern University, on the practice-changing abstracts presented at the 2020 ASCO-GU virtual meeting. The trio weigh the importance and real-world implications of the ACIS study for mCRPC, EV-301 for advanced or metastatic urothelial carcinoma as well as CheckMate 274 for muscle-invasive dis...
Mar 02, 2021•1 hr 18 min
Chadi welcomes back Jack West (@JackWestMD), MD, associate clinical professor and medical oncologist, City of Hope Comprehensive Cancer Center, and Nathan Pennell (@n8pennell), MD, PhD, thoracic medical oncologist, director of the thoracic oncology program and director of clinical research, Cleveland Clinic, to the show. The task was to break down the ADAURA trial again, but to go beyond ADUARA and explore the use of various endpoints in lung cancer and how trials should be optimally designed to...
Feb 23, 2021•54 min
David Fajgenbaum (@DavidFajgenbaum), MD, MBA, MSc, assistant professor in the department of medicine at the University of Pennsylvania, as well as the associate director of patient impact for the Penn Orphan Disease Center, joins the show to talk about his experience writing and receiving feedback on the national bestseller “Chasing My Cure” as a survivor of Castleman disease – a commentary on how he turned hope into action and discovered an old drug that had never been researched in Castleman d...
Feb 16, 2021•1 hr 1 min
Vincent Rajkumar, (@VincentRK), MD, hematologist at the Mayo Clinic (Rochester, MN), joins the show to guest host a debate between Sagar Lonial (@SagarLonialMD), MD, FACP, chief medical officer of Winship Cancer Institute of Emory University, and Rafael Fonseca, (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center. These multiple myeloma “gurus” dive into imaging, smoldering disease, endpoints, maintenance, minimal residual disease, and so much more.
Feb 09, 2021•1 hr 13 min
Tanios S. Bekaii-Saab (@GIcancerDoc), MD, professor of medicine and director of the GI oncology program at the Mayo Clinic (Phoenix, AZ), joins the show to highlight the research with significant clinical application presented at the virtual ASCO-GI meeting, including KEYNOTE-177 and ATOMIC in colorectal cancer, atezolizumab plus bevacizumab for first-line HCC, a survival update in the POLO trial and utility of radiation for pancreatic cancer, PD-1 inhibitors for first-line and adjuvant treatmen...
Feb 02, 2021•58 min
Stacie Dusetzina (@DusetzinaS), PhD, associate professor of health policy, Vanderbilt University Medical Center, joins the show to expound on the changes that have been made to Medicare Part D since its inception during the Bush administration, how Part D is failing the older population in need of expensive drugs, and the counterintuitive state of generic drug affordability for Part D recipients. Chadi and Stacie then discuss how changes in the presidential administration will impact Part D cove...
Jan 26, 2021•47 min
Chadi welcomes back Alison Bateman-House, (@ABatemanHouse), MPH, PhD, medical ethicist at New York University’s School of Medicine, to break down COVID-19 vaccine distribution and mandates. Why has vaccine distribution not been an efficient and effective process? Are the right people being prioritized in the vaccine pecking order? Should vaccine doses be immediately available to anybody and everybody to make strides toward herd immunity? Should a “first dose only” vaccine approach be adopted to ...
Jan 19, 2021•57 min
Rohin Francis (@MedCrisis), cardiologist in the UK, brings his expertise and unique sense of humor to the show to share how he’s combined comedy with medical education through his Twitter and YouTube presence, how he sifts through the vast expanse of COVID-19 research for data that is useful and legitimate, the apparent inability to have an open scientific debate on Twitter without being chastised or judged for your viewpoints, and so much more. Check out Dr. Francis’ videos at https://www.medli...
Jan 12, 2021•1 hr 2 min
Aaron Goodman (@AaronGoodman33), MD, hematologist/oncologist, University of California San Diego, and Jatin Shah (@JatinShahMD), MD, executive vice president and chief medical officer, Karyopharm Therapeutics, join the show for a deep consideration of oncology drug approvals in the context of RCTs, RWE, surrogate endpoints, and outcomes. The larger discussion is framed around Karyopharm’s STORM study of selinexor in refractory multiple myeloma and whether the FDA had enough convincing data to ap...
Jan 05, 2021•1 hr 6 min
In an enthralling yet informative roundtable discussion, Chadi hosts Saurabh Jha (@RogueRad), MD, radiologist and frequent guest of the show; Vinay Prasad (@VPrasadMDMPH), MD, MPH, hematologist/oncologist and former guest of the show; and Sally "Loyal Listener"(@barttels2), patient advocate, to breakdown 2020 like only they can. These titans of the MedTwitter world dissect and opine on lessons to be learned from COVID-19 (warts and all), the diminishing space for public discourse and healthy deb...
Dec 29, 2020•1 hr 27 min
Rafael Fonseca (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center, shares with Chadi his picks for the most clinically applicable multiple myeloma studies coming out of the ASH virtual meeting, including notes on transplantation, frontline therapy, the “belle of the ball” bispecific antibodies, CAR-T therapies, and MRD monitoring.
Dec 22, 2020•47 min
Laura Lee (@lauraelee), JD, a lawyer by training and journalist in North Carolina, brings her unique perspective to the show to discuss how language used on social media to describe the outcomes of clinical trials and the tolerance of therapies in a patient population can be damaging to patients on an individual level. She expresses some of her larger concerns in the way medical information is displayed and discussed online, including the tone that is used, how quality of life measures fall shor...
Dec 15, 2020•42 min
Yousuf Zafar (@yzafar), MD, GI oncologist and associate professor of medicine, Duke University, highlights perspectives that are missing from the “general rubric” of value-based care in oncology, how real-world evidence (RWE) can help augment takeaways from clinical trial data, issues of capturing the patient voice in real-world data and electronic health records, and how the FDA is utilizing RWE for expanding drug indications. Dr. Zafar shares where he sees the intersection between RWE and valu...
Dec 01, 2020•57 min
Alison Bateman-House (@ABatemanHouse), MPH, PhD, medical ethicist at New York University’s School of Medicine, explains the distinction between direct-to-consumer (DTC) advertising of doctors and drugs to that of consumer goods, as well as regulatory and ethical concerns of DTC advertising on the part of hospitals and drugs. Chadi and Dr. Bateman-House grapple with questions of whether healthcare is simply a consumer good or if it is something more and whether DTC advertising should be banned in...
Nov 24, 2020•59 min
Jill Feldman (@jillfeldman4), lung cancer survivor and advocate, shares her familial history of lung cancer that drove her to advocacy work long before her own diagnosis of EGFR-positive disease, as well as her treatment courses with erlotinib and subsequent SBRT for many years before osimertinib. Jill then describes her “journey” in advocacy, beginning with self-advocacy and the LUNGevity Foundation, independent research advocacy and representing lung cancer patients, and co-founding the EGFR R...
Nov 17, 2020•1 hr 5 min
Ameet Kini (@AmeetRKini), MD, PhD, hematopathologist, and Patrick Hagan, MD, hematologist/oncologist, both at Loyola University Medical Center, deliberate on the clinical importance of MRD and how clinicians should utilize it, optimal techniques for detecting MRD in various diseases, the gap between academia and the community when it comes to MRD knowledge, the potential of MRD as a surrogate marker, and how to reconcile discordant MRD results from different vendors.
Nov 10, 2020•54 min
Vincent Rajkumar (@VincentRK), MD, hematologist at the Mayo Clinic (Rochester, MN), shares the distinction between conflicts of interest that guide individual physicians and those that guide entire practices, what types of conflicts should be collected as “material” and which should be disregarded (eg, “transfer of value” payments), issues with disclosure expectations in modern medical research, and an idea to create standards for more appropriate and warranted disclosures. Watch a previous disc...
Oct 27, 2020•56 min
Chadi facilitates a discussion between three GU oncologists on the latest research and treatment updates in the field. Rana McKay (@DrRanaMcKay), MD, UC San Diego, Petros Grivas (@PGrivasMDPhD), MD, PhD, Fred Hutchinson Cancer Research Center, and Toni Choueiri (@DrChoueiri), MD, Dana-Farber Cancer Institute, debate the practice-changing potential of chosen papers and abstracts presented at ASCO and ESMO, including updated data on the final OS in the PROFOUND trial, context and implications of t...
Oct 20, 2020•1 hr 7 min
John Doench (@JohnDoench), PhD, Associate Director of the Genetic Perturbation Platform, Broad Institute of MIT and Harvard, joins Chadi for a fascinating discussion on the history of CRISPR as a scientific breakthrough, the ease of merging CRISPR technology into human cells, challenges remaining for CRISPR to become a widely used clinical tool and ultimately helping patients, and much more.
Oct 13, 2020•50 min
In the inaugural episode of Healthcare Unfiltered, host Chadi Nabhan invites cardiologists Venk Murthy (@venkmurthy), MD, University of Michigan, and Anish Koka (@anish_koka), MD, private practice in Philadelphia, to contextualize the effects of COVID-19 on the heart, as explained in a flawed JAMA Cardiology publication that was close to having such trickle down effects as cancelling college sports across the US. The trio explains how the study should not be used to treat patients with preexisti...
Oct 06, 2020•1 hr 9 min
